At least 16 European countries, including Germany, France, Italy and Ireland, have temporarily suspended use of the AstraZeneca plc (LON: AZN) COVID-19 vaccine over fears it may cause blood clots in some recipients. The manufacturer of the vaccine, which has been approved for use in Australia, insists there is no risk from the product's use.
Studies conducted during the development of the vaccine, as well as observations during the public rollout, do not indicate any level of heightened threat.
With an effective vaccine distribution contributing to recent market confidence, could fears over the vaccine's safety impact the ASX?
Image source: Getty Images
Australian Government continuing vaccine rollout
Treasurer Josh Frydenberg said Australia will not pause the AstraZeneca vaccine rollout.
"[Australian health experts] have not found any causal link between the vaccine and blood clots," he told Sky News this morning.
"…the vaccine rollout will continue."
Similarly, Prime Minister Scott Morrison said the Therapeutics Good Administration (TGA) does not need to reconsider approving the vaccine. The PM has previously cited a thorough examination of the efficacy and safety of the AstraZeneca shot as a reason for Australia's slower than expected inoculation speed.
While the TGA has approved the imported AstraZeneca vaccine for use in Australia, it is yet to approve the locally manufactured variant. The CSL Limited (ASX: CSL) mass-produced vaccine will provide 50 million doses for Australia and its neighbours.
What a delayed rollout could mean for the ASX
The S&P/ASX 200 Index (ASX: XJO) is up 2,227 points (or 49%) since the coronavirus induced mass sell-off of March last year. Arguably, part of the reason for the strong recovery can be attributed to optimism that vaccines will lead to a quick end to the pandemic.
And European markets slid lower overnight as news more countries had suspended their vaccine rollouts spooked investors.
Again, the Australian government does not intend to pause the AstraZeneca vaccine in Australia and there is no evidence of direct harm caused by it.
However, the share market isn't always a rational beast. Any fears over a delay to the vaccine's rollout in Australia could scare off some investors here.
The economic impacts of COVID-19 and subsequent restrictions devasted some of Australia's largest companies, particularly those operating in the travel sector or those which are heavily reliant on open borders for their revenue.
It will be interesting to see whether ASX shares such as CSL, Qantas Airways Limited (ASX: QAN), Flight Centre Travel Group Ltd (ASX: FLT), and A2 Milk Company Ltd (ASX: A2M) see any fallout from reports surrounding the AstraZeneca vaccine when today's session kicks off.
